Carlos Guerrero
Family · Lancaster, CANPI 1699855080
Payments from drug & device makers
Across 323 payments — averaging $24.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- Amgen$1K
- Bayer$650
- Merck$573
- Boehringer Ingelheim$517
- Lilly USA, LLC$506
- plus $3K from 29 others
What the payments were for
- Food & beverage$7,830100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 64 | $1,445 |
| Amgen(2 entities) | 51 | $1,064 |
| Bayer | 16 | $650 |
| Merck | 23 | $573 |
| Boehringer Ingelheim | 22 | $517 |
| Lilly USA, LLC | 22 | $506 |
| Otsuka America Pharmaceutical, Inc. | 15 | $314 |
| AstraZeneca | 15 | $309 |
| Gilead | 3 | $266 |
| Xeris Pharmaceuticals, Inc. | 11 | $223 |
| Regeneron Healthcare Solutions, Inc. | 3 | $183 |
| GSK | 9 | $180 |
| Mannkind Corporation | 3 | $164 |
| Novartis | 8 | $157 |
| Abbott | 7 | $153 |
| AbbVie | 7 | $144 |
| Sanofi-aventis U.S. LLC | 6 | $141 |
| Dexcom, Inc. | 4 | $103 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 6 | $98 |
| Ardelyx, Inc. | 4 | $85 |
| Pfizer | 4 | $67 |
| Ironwood Pharmaceuticals, Inc | 3 | $62 |
| Kowa Pharmaceuticals America, Inc. | 1 | $48 |
| Lundbeck LLC | 2 | $47 |
| Verity Pharmaceuticals Inc. | 1 | $46 |
| Mylan Specialty L.p. | 2 | $44 |
| Corcept Therapeutics | 2 | $41 |
| Biohaven Pharmaceuticals, Inc. | 2 | $35 |
| Harmony Biosciences LLC | 1 | $34 |
| Electromed, Inc. | 1 | $27 |
| Verona Pharma, Inc. | 1 | $27 |
| Tandem Diabetes Care, Inc. | 1 | $26 |
| Tolmar, Inc. | 1 | $20 |
| Alkermes, Inc. | 1 | $16 |
| Alnylam Pharmaceuticals Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,830 in reported general payments places this provider in the 95th percentile of 10,634 family providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 197 | $242,118 |
| JardianceEmpagliflozin | 172 | $190,260 |
| LinzessLinaclotide | 163 | $123,534 |
| SynjardyEmpagliflozin/Metformin Hcl | 121 | $107,108 |
| KerendiaFinerenone | 88 | $103,514 |
| FarxigaDapagliflozin Propanediol | 91 | $96,515 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 97 | $85,062 |
| EliquisApixaban | 76 | $81,297 |
| RybelsusSemaglutide | 59 | $76,473 |
| MounjaroTirzepatide | 67 | $72,225 |
| EntrestoSacubitril/Valsartan | 57 | $63,869 |
| XareltoRivaroxaban | 45 | $56,330 |
| MyrbetriqMirabegron | 80 | $56,152 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 35 | $44,004 |
| TrulicityDulaglutide | 31 | $34,652 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Synjardy, Synjardy Xr, Stiolto Respimat, Tradjenta | $517 | $381,365391 claims |
| Novo NordiskOzempic, Rybelsus | $1,445 | $318,591256 claims |
| AbbVieLinzess, Namzaric | $144 | $151,738185 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Brilinta | $309 | $134,520146 claims |
| Lilly USA, LLCMounjaro, Trulicity | $506 | $106,87798 claims |
| BayerKerendia | $650 | $103,51488 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $180 | $103,489137 claims |
| PfizerEliquis | $67 | $81,29776 claims |
| NovartisEntresto | $157 | $63,86957 claims |
| MerckVerquvo, Januvia | $573 | $42,01644 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $98 | $33,36911 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $314 | $31,56013 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 10,634 family providers in California.
Other family in Lancaster
- Lori RobertsonChino Hills$475K
- Annette ShonLos Angeles$406K
- Nancy GardettoSan Diego$394K
- Lisa HigginsHanford$311K
- Jennifer TougasBakersfield$302K
- Kim SchaferSacramento$288K
- Dawn MeyerSan Diego$270K
- Jennifer KangCerritos$255K
- Jenine StoneEscondido$231K
- Erin DwyerSan Diego$189K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.